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Association scan of 14,500 nsSNPs in four common diseases
identifies variants involved in autoimmunity
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Abstract
We have genotyped 14,436 nsSNPs and 897 MHC tagSNPs in 1000 independent cases of
Ankylosing Spondylitis (AS), Autoimmune Thyroid Disease (AITD), Multiple Sclerosis and
Breast Cancer. Comparing each of these diseases against a common control set of 1500 unselected
healthy British individuals, we report initial association and independent replication of two new
loci for AS, ARTS1 and IL23R, and confirmation of the previously reported AITD association
with TSHR and FCRL3. These findings, enabled in part by expanding the control reference group
with individuals from the other disease groups to increase statistical power, highlight important
new possibilities for autoimmune regulation and suggest that IL23R may be a common
susceptibility factor for the major ‘seronegative’ diseases.
Genome-wide association scans are currently revealing a number of new genetic variants for
common diseases; eg1-11. We have recently completed the largest and most comprehensive
scan conducted to date, involving genome-wide association studies of 2000 individuals from
each of seven common disease cohorts and 3000 common control individuals using a dense
panel of >500k markers12. In parallel with this scan, we conducted a study of 5,500
independent individuals with a genome-wide set of non-synonymous coding variants, an
approach which has recently yielded new findings for Type 1 diabetes and Crohn’s disease
and which has been proposed as an efficient complementary approach to whole genome
scans13-15. Here we report several new replicated associations in our scan of nsSNPs in
1500 shared controls and 1000 individuals from each of 4 different diseases: Ankylosing
Spondylitis (AS), Autoimmune Thyroid Disease/Graves’ Disease (AITD), Breast Cancer
(BC) and Multiple Sclerosis (MS).
RESULTS
Initial genotyping was performed with a custom-made Infinium array (Illumina) and
involved 14,436 nsSNPs (assays were synthesized for 16,078 nsSNPs). At the time of study
inception, this comprised the complete set of experimentally validated nsSNPs with MAF >
1% in Caucasian samples. In addition, because three of the diseases were of autoimmune
aetiology, we also typed a dense set of 897 SNPs throughout the major histocompatibility
complex (MHC) which together with 348 nsSNPs in this region provided comprehensive tag
SNP coverage (r2 ≥ 0.8 with all SNPs in ref16). Finally, 103 SNPs were typed in
pigmentation genes specifically designed to differentiate between population groups. Similar
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to previous studies, our data revealed that detailed assessment of initial data is critically
important to the process of association inference, as biases in genotype calling lead to clear
inflation of false positive rates12,17. This inflation is exaggerated in nsSNP data because they
tend to have lower allele frequencies than otherwise anonymous genomic SNPs and
genotype calling is often most difficult for rare alleles. If only cursory filtering had been
applied in the present case, a large number of striking false-positives would have emerged
(Supplementary Figures 1-4). Table 1 displays the total number of SNPs and individuals
remaining after genotype and sample quality control procedures (see Methods).
Association with the MHC
The strongest associations observed in the study were between SNPs in the MHC region and
the three auto-immune diseases studied, AS, AITD and MS, with p-values of <10-20 for each
disease (Figure 1). No association of the MHC was seen with BC (p > 10-4 across the
region). For each of the autoimmune diseases, the maximum signal is centered around the
known HLA-associated genes (ie, HLA-B in AS, HLA-DRB1 in MS and the MHC Class I-
II for AITD), but in all cases it extends far beyond the specific associated haplotype(s). For
example, in AS, association was observed at p < 10-20 across ~ 1.5 Mb. Given the well-
known large effect of B27 with AS (odds ratio 100-200 in most populations), the extent of
this association signal reflects the fact that with such large effects, even very distant SNPs in
modest LD will reveal indirect evidence for association. Strong signals like these may also
cloud the evidence for additional HLA loci18. Disentangling similar patterns of association
within the MHC has proven extremely challenging in the past and will be addressed in
future studies of these data. Here we focus specifically on the nsSNP results.
Association with nsSNPs
A major advantage of the WTCCC design is the availability of multiple disease cohorts
which are similar in terms of ancestry and which have been typed on the same genetic
markers12,17. Assuming that each disease has at least some genetic loci that differ between
diseases, it should be possible to increase power to detect association by combining the other
three case groups with the 58C controls19. For each disease we therefore conducted two
primary analyses: (1) testing nsSNP associations for each disease against the 1958 Birth
Cohort controls (58C); and (2) testing the same associations for each disease against an
expanded reference group comprising the combined cases from the other three disease
groups plus individuals from the 58C. A similar set of analyses was conducted for each of
the autoimmune disorders against a reference group comprising 58C+BC, but the results
were very similar to those for the fully expanded groups so here we describe the larger
sample (see Supplementary Table 1). In addition, since it is possible that different
autoimmune diseases share similar genetic etiologies, we also compared a combined AS,
AITD and MS group against the combined set of BC patients and 58C controls. All of our
analyses are reported without regard to specific treatment of population structure, as the
degree of structure in our final genotype data is not severe (Genomic Control20 λ = 1.07 to
1.13 in the 58C-only datasets; λ = 1.03 to 1.06 in the expanded reference group
comparisons, see Table 2), consistent with our recent findings from 17,000 UK individuals
involving the same controls12.
nsSNP association results (i.e. excluding the MHC region) for each of the four disease
groups against the 58C controls are shown in Figure 2 and Table 3. Two SNPs on
chromosome 5 reached a high-level of statistical significance for AS (rs27044: p = 1.0 ×
10-6; rs30187: p = 3.0 × 10-6). This level of significance exceeds the 10-5-10-6 thresholds
advocated for gene-based scans21, as well as the oft-used Bonferroni correction at p< 0.05
(see refs12,21 for a discussion of genome-wide association significance). Both of these
markers reside in the gene for ARTS1 (ERAAP, ERAP1), a type II integral transmembrane
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aminopeptidase with diverse immunological functions. Four additional SNPs display
significance at p< 10-4, with an increasing number of possible associations at more modest
significance levels. Several of the more strongly associated SNPs or others in the same
genes have previously been associated with the particular disease, and for others there exists
functional evidence for their involvement in the particular condition. These include SNPs in
the genes FCRL3 and FCRL5 in the case of AITD, IL23R in the case of AS, MEL-18 in the
case of BC, and IL7R for MS. The complete list of single-marker association results is
provided in Supplementary Table 1.
The results for analyses involving the expanded reference group are presented in
Supplementary Figure 5 and Supplementary Table 1. Many of the SNPs that showed
moderate to strong evidence for association in the initial analysis revealed substantially
increased significance with the larger reference group. Notably, these included the SNPs
rs27044 (p = 4.0 × 10-8) and rs30187 (p = 2.1 × 10-7) in ARTS1, as well as several other
variants in this gene. A second SNP, rs7302230 in the Calsyntenin-3 gene on chromosome
12, showed substantially stronger evidence for association in the expanded reference group
analysis (p = 5.3 × 10-7) relative to the 58C-only results (p = 1.1 × 10-4). Results of the
expanded group also showed elevated results for several SNPs which did not appear
exceptional in the original (non-combined) analyses, including SNPs in several candidate
genes such as sialoadhesin22 and complement receptor 1 for AS, PIK3R2 for MS, and C8B,
IL17R and TYK2 in the combined autoimmune disease analysis. SNP rs3783941 in the
thyroid stimulating hormone receptor (TSHR) gene emerged as amongst the most significant
in the expanded reference group analyses of AITD (p = 2.1 × 10-5). Several polymorphisms
in the TSHR have previously been associated with Graves’ disease23,24. This known
association did not reach even the modest significance level of 10-3 in the original analyses,
but adding an additional 3000 further reference samples delineated it from the background
noise and further supports the original independent report.
ARTS1 association confirmed in an independent cohort
In order to validate the most exceptional findings from the initial study, we genotyped the
ARTS1, CLSTN3 and LNPEP SNPs in 471 independent AS cases and 625 new controls (all
North American Caucasian). Table 4 shows the results of the genes examined for AS. The
data strongly suggest that the ARTS1 association is genuine. All ARTS1 nsSNPs reveal
independent replication in the same direction of effect, with replication significance levels
ranging from 4.7 × 10-4 to 5.1 × 10-5. When combined with the original samples, the results
reveal striking evidence for association with AS (p = 1.2 × 10-8 to 3.4 × 10-10). The
population attributable risk25 contributed by the most strongly associated marker in the
North American dataset (rs2287987) is 26%.
Association was also confirmed with marker rs2303138 in the LNPEP gene, which lies
127kb 3′ of ARTS1. This marker is in strong LD with ARTS1 markers (D’ = 1, rs27044 -
rs2303138). We tested the interdependence of the ARTS1 and LNPEP associations using
conditional logistic regression. The remaining association at LNPEP is weak after
controlling for ARTS1 (p = 0.01), whereas the association at ARTS1 remains strong after
controlling for LNPEP (p = 2.7 × 10-6), suggesting that the LNPEP association may only be
secondary to LD with a true association at ARTS1.
No association was seen with CLSTN3 in the confirmation set. The US controls exhibited
the same allele frequency as the UK controls (5%) but the allele frequency in the US cases
was less than that of the UK cases (6% vs 8%), suggesting no association in the US samples
and substantially reducing the significance of the combined data. Calystenin-3 is a post-
synaptic neuronal membrane protein, and is an unlikely candidate gene for involvement in
inflammatory arthritis. The failure to replicate this association suggests that our replication
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sample size is insufficient to detect the modest effect or it was a false positive in the initial
scan.
IL23R variants confer risk of AS
The IL23R variant rs11209026, whilst not striking in the initial nsSNP scan (p = 1.7 × 10-3),
is of particular interest as it was recently associated with both Crohn’s Disease26,27 and
psoriasis28, conditions which commonly co-occur with AS. To better define this
association, 7 additional SNPs in IL23R were genotyped in the same 1000 British AS cases
and 1500 58C controls as well as the North American Caucasian replication samples (Table
4). In the WTCCC dataset, strong association was seen in 7 of 8 genotyped SNPs (p ≤ 0.008,
including the original nsSNP rs11209026), with the strongest association seen at rs11209032
(p = 2.0 × 10-6). In the replication dataset, association was observed with all genotyped
SNPs (p ≤ 0.04), with peak association observed with marker rs10489629 (p = 4.2 × 10-5).
In the combined dataset, the strongest association observed was with SNP rs11209032 (odds
ratio 1.3, 95% CI 1.2 - 1.4, p = 7.5 × 10-9). The attributable risk for this marker in the
replication cohort is 9%. Conditional logistic regression analyses did not reveal a single
primary disease-associated marker, with residual association remaining after having
controlled for association at the remaining SNPs. Considering only AS cases who self-
reported as not having inflammatory bowel disease (n = 1066) the association remained
strong and was still strongest at rs11209032 (p = 6.9 × 10-7), indicating that there is a
primary association with AS and that the observed association was not due to coexistent
clinical inflammatory bowel disease.
In contrast to the pleiotropic effects of IL23R, the ARTS1 association evidence appears
confined to AS. We genotyped the five AS-associated SNPs in 755 British Crohn’s disease
and 1011 ulcerative colitis cases, and 633 healthy controls. No association was seen with
either UC or CD (Armitage trend p > 0.4 for all markers).
FCRL3 confirmed in AITD pathogenesis
In addition to the AS replications, we attempted to confirm and extend the FCRL3
association in AITD. The SNP rs7522061 in the FCRL3 gene was recently reported to be
associated with AITD29 and two other autoimmune diseases, rheumatoid arthritis and
systemic lupus erythematosus30. Our initial association evidence (p = 2.1 × 10-4) likely
reflects the signal of the originally detected polymorphism since the level of linkage
disequilibrium (LD) is high across this gene. In fact, the entire 1q21-q23 region (which
includes another gene, FCRL5, flagged in our scan) has also been implicated in several
autoimmune diseases including psoriasis and multiple sclerosis31,32.
On the basis of the original findings on 1q21-q23, the original cohort was increased from
1,000 to 2,500 Graves Disease (GD) cases and we used 2,500 different 1958 cohort controls.
Eight SNPs that tagged the FCRL3 and FCRL5 gene regions were selected and typed in all
5,000 samples using an alternative genotyping platform. SNP rs3761959, which tags
rs7522061 and rs7528684 (previously associated with RA and GD), was associated with GD
in this extended cohort (Table 5), therefore, confirming the original result. In total, three of
the seven FCRL3 SNPs showed some evidence for association (p < .05) with SNP
rs11264798 being the most associated of the tag SNPs, p = 4.0 × 10-3. SNP rs6667109 in
FCRL5, which tagged SNPs rs6427384, rs2012199 and rs6679793, all found to be weakly
associated in the original study, showed little evidence of association in this extended
cohort.
and Page 4
Nat Genet. Author manuscript; available in PMC 2009 May 11.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
DISCUSSION
Our scan of nsSNPs has identified and validated two new genes for AS (ARTS1 and
IL23R), confirmed and extended markers in the TSHR and FCRL3 genes which have
previously been associated with AITD, and provided a dense set of association data for
AITD, AS and MS across the MHC region. The challenge now is to design functional
studies that will reveal how variation in these genes translates into physiological processes
that influence disease risk.
From a functional perspective, the ARTS1 and IL23R genes represent excellent biological
candidates. ARTS1 has two known functions, either of which may explain its association
with AS. Within the endoplasmic reticulum, ARTS1 is involved in trimming peptides to the
optimal length for MHC Class I presentation33,34. AS is primarily an HLA Class I
mediated autoimmune disease35, with >90% of cases carrying the HLA-B27 allele. How
B27 increases risk of AS is unknown, but if the mechanism of association of ARTS1 with
the disease is through effects on peptide presentation, this would inform research into the
mechanism explaining the association of B27 with AS. The second known function of
ARTS1 is that it cleaves cell surface receptors for the pro-inflammatory cytokines IL-1
(IL-1R2)36, IL-6 (IL-6Rα)37 and TNF (TNFR1)38, thereby downregulating their signaling.
Genetic variants that alter the functioning of ARTS1 could therefore have pro-inflammatory
effects through this mechanism.
As well as AS, polymorphisms in IL23R have been recently documented in Crohn’s Disease
26,27 and psoriasis 28, suggesting that this gene is a common susceptibility factor for the
major ‘seronegative’ diseases, at least partially explaining their co-occurrence. IL-23R is a
key factor in the regulation of a newly defined effector T-cell subset, TH17 cells. TH17 cells
were originally identified as a distinct subset of T-cells expressing high levels of the pro-
inflammatory cytokine IL-17 in response to stimulation, in addition to IL-1, IL-6, TNFa,
IL-22 and IL-25 (IL-17E). IL-23 has been shown to be important in the mouse models
experimental autoimmune encephalomyelitis39, collagen-induced arthritis40 and mouse
models of inflammatory bowel disease41, but has not been studied in AS, either in humans
or animal models of disease. These studies show that blocking IL-23 reduces inflammation
in these models, suggesting that the IL23R variants associated with disease are pro-
inflammatory. Successful treatment of Crohn’s disease has been reported with anti-IL-12p40
antibodies, which block both IL-12 and IL-23, as these cytokines share the IL-12p40
chain42. No functional studies of IL23R variants have been reported to date, and it is
unclear to what extent findings in studies targeting IL-23 can be generalised to mechanisms
by which IL23R variation affects disease susceptibility. Our genetic findings provide a
major novel insight into the aetiopathogenesis of AS, and suggest that treatments targeting
IL-23 may prove effective in this condition, but clearly much more needs to be understood
about the mechanism underlying the observed association.
Despite the successful identification of the ARTS1 and IL23R genes, it is likely that
additional real associations are either present in our data but with modest effect sizes, or that
our focus on non-synonymous coding changes led us to miss real genes. For example, we
found no evidence for association at even a nominal p < 0.05 in or within 2 Mb of the
recently reported and validated breast cancer gene FGFR33,43 (2 nsSNPs in FGFR3 were
included in our panel, rs1078816 and rs755793; the former yielded p = 0.12 and the latter
was monomorphic in these samples), nor in or near any of the other suggestive breast cancer
genes reported in refs3,43. Lack of statistical power in 1000 cases and 1500 controls is a
likely contributor to this lack of replication, but some of these loci, notably FGFR3, appear
to be intronic and thus would likely have been missed even with larger samples.
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The issue of statistical power is emphasized in studies of non-synonymous coding changes,
which have a greater number of rare variants than other genetic variants and thus will
require even larger sample sizes unless the effect sizes are larger. Other analytical
approaches, such as assessing evidence for association between clusters of rare variants
rather than individual loci may prove highly informative in this regard44, but most of the
nsSNPs available in this study exist either by themselves in each gene or with 1-2 others,
which precludes these assessments (Supplementary Figure 6). In our analyses, ARTS1 was
the only locus showing exceptional statistical significance in the scan of 1000 cases and
1500 controls, thus emphasizing the need for greater statistical power. We increased power
by expanding the controls, or ‘reference set’, to include some or all of the other disease
samples. In doing so, ARTS1 showed strong association evidence, the IL23R SNPs
increased to a level that began to delineate them from background noise, and the AITD/
TSHR confirmation emerged. This demonstration of increased statistical power by
combining multiple datasets is timely given the international impetus to make genotype data
available to the scientific community. Future investigations will be needed to assess the
power vs confounding effects and the statistical corrections needed to combine more
heterogeneous samples from broader sampling regions.
These results also highlight the question of how much information may be missed by
focusing on coding SNPs rather than searching more broadly over the genome at large. This
question is relevant because the trade-off between SNP panel selection and sample size to
genotype is a salient factor in every genome-wide study design. In the HapMap data45, a
substantial portion of the common non-synonymous variation in our nsSNP set is captured
by available genome-wide panels (about 65% of common (MAF > 5%) nsSNPs in the
Illumina Human NS-12 Beadchip are tagged with an r2 > .8 using the Affymetrix 500K
chip, rising to 90% for the Illumina HumanHap300 which includes almost all of the nsSNPs
from the NS-12 Beadchip). The four primary associated variants flagged in our study (i.e., in
ARTS1, IL23R, TSHR and FCRL3) would have been detected using any of the genome-
wide panels, since either the markers themselves or a SNP in high LD with them (r2 ≥ .78),
are present on the genome-wide chips. This LD relationship also emphasizes the fact that
observing an association with a nsSNP does not necessarily imply that the nsSNP is causal,
as it may be indirectly associated with other genetic variants in or outside the gene. Given
this high degree of overlap, the continuously increasing coverage of many available
genotyping products and concomitant pressures to decrease assay costs, these data suggest
that future gene-centric scans will be efficiently subsumed by the more encompassing and
less hypothesis-driven genome-wide SNP panels.
METHODS
Subjects
Individuals included in the study were self-identified as white Europeans and came from
mainland UK (England, Scotland and Wales, but not Northern Ireland). The 1500 control
samples were from the British 1958 Birth Cohort (58C, also known as the National Child
Development Study), which included all births in England, Wales and Scotland during one
week in 1958. Recruitment details and diagnostic criteria for each of the four case groups
and the 58C are further described in the Supplementary Methods online.
Sample QA/QC
Genome-wide Identity by State (IBS) sharing was calculated for each pair of individuals in
the combined sample of cohorts in order to identify first and second degree relatives that
might contaminate the study. One subject from any pair of individuals who shared < 400
genotypes IBS = 0 and/or > 80% alleles IBS was removed from all subsequent analyses (i.e.
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the individual with the most missing genotypes). In order to identify individuals who might
have ancestries other than Western European, we merged each of our cohorts with the 60
CEU founder, 60 YRI founder, and 90 JPT and CHB individuals from the International
HapMap Project45. We calculated genome-wide identity by state distances for each pair of
individuals (i.e. one minus average IBS sharing) on those markers shared between HapMap
and our non-synonymous panel, and then used the multidimensional scaling option in R to
generate a two dimensional plot based upon individuals’ scores on the first two principal
coordinates from this analysis (Supplementary Figure 2). Any WTCCC sample that was not
present in the main cluster with the CEU individuals was excluded from subsequent
analyses. Finally, any individual with >10% of genotypes missing was removed from the
analysis. The number of individuals remaining after these quality control measures is
displayed in Table 1.
Genotyping
We genotyped a total of 14,436 nsSNPs across the genome on all case and control samples.
Because three of the diseases were of autoimmune etiology, we also typed an additional 897
SNPs within the MHC region, as well as 103 SNPs in pigmentation genes specifically
designed to differentiate between population groups. SNP genotyping was performed with
the Infinium I assay (Illumina) which is based on Allele Specific Primer Extension (ASPE)
and the use of a single fluorochrome. The assay requires ~250 ng of genomic DNA which is
first subjected to a round of isothermal amplification generating a “high complexity”
representation of the genome with most loci represented at usable amounts. There are two
allele specific probes (50mers) per SNP each on a different bead type; each bead type is
present on the array 30 times on average (minimum 5), allowing for multiple independent
measurements. We processed six samples per array. Clustering was performed with the
GenCall software version 6.2.0.4 which assigns a quality score to each locus and an
individual genotype confidence score (GC score) which is based on the distance of a
genotype from the centre of the nearest cluster. First, we removed samples with more than
50% of loci having a score below 0.7 and then all loci with a quality score below 0.2. Post
clustering we applied two additional filtering criteria: (i) omit individual genotypes with a
GC score < 0.15 and (ii) remove any SNP which had more than 20% of its samples with GC
scores below 0.15. The above criteria were designed so as to optimize genotype accuracy
whilst minimizing uncalled genotypes.
Statistical Analysis
Markers that were monomorphic in both case and control samples, SNPs with > 10%
missing genotypes, and SNPs with differences in the amount of missing data between cases
and controls (p < 10-4 as assessed by χ2 test) were excluded from all analyses involving that
case group only. In addition any marker which failed an exact test of Hardy-Weinberg
equilibrium in controls (p < 10-7) was excluded from all analyses46.
Cochran-Armitage Tests for trend47 were conducted using the PLINK program48. For the
present analyses, we used the significance thresholds of p < 10-4 – 10-6, as suggested for
gene-based scans with stronger prior probabilities than scans of anonymous markers21. In
the present context, the lower thresholds are similar to Bonferroni significance levels
(Bonferroni-corrected p = .05 corresponds to nominal p = 3 × 10-6). The conditional logistic
regression analyses involving the LNPEP and ARTS1 SNPs were performed using Purcell’s
WHAP program49.
We manually rechecked the genotype calls of every nsSNP with an asymptotic significance
level of p < 10-3 by inspecting raw signal intensity values and their corresponding automated
genotype calls. Interestingly, this flagged an additional 33 markers with clear problems in
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genotype calling, which were subsequently excluded from all analyses (see Supplementary
Figure 4 for an example). These results indicate that this genotyping platform generally
yields highly accurate genotypes, but errors do occur and they can be distributed non-
randomly between cases and controls despite stringent QC procedures. It is imperative to
check the clustering of the most significant SNPs to ensure that evidence for associations are
not a result of genotyping error.
Whilst great lengths were taken to ensure our samples were as homogenous as possible in
terms of genetic ancestry, even subtle population substructure can substantially influence
tests of association in large genome-wide analyses involving thousands of individuals50. We
therefore calculated the genomic-control inflation factor, λ20, for each case-control sample
as well as in the analyses where we combined the other case groups with the control
individuals (Table 2). In general, values for λ were small (~1.1) indicating a small degree of
substructure in UK samples which induces only a slight inflation of the test statistic under
the null hypothesis, consistent with the results from our companion paper12. We, therefore,
present uncorrected results in all analyses reported.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Minus log10 p values for the Armitage test of trend for MHC association with Ankylosing
Spondylitis (top panel), Auto-Immune Thyroid Disease (middle panel), and Multiple
Sclerosis (bottom panel). Note in particular how evidence for association extends along very
long regions of the MHC, reflecting statistical power to detect association even when
linkage disequilibrium amongst SNPs is relatively low and/or the possibility of multiple
disease-predisposing loci.
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Figure 2.
Minus log10 p values for the Armitage test of trend for genome-wide association scans of
ankylosing spondylitis, auto-immune thyroid disease, breast cancer and multiple sclerosis.
The spacing between SNPs on the plot is uniform and does not reflect distances between the
SNPs. The vertical dashed lines reflect chromosomal boundaries. The horizontal dashed
lines display the cutoff of p = 10-6. Note that SNPs within the MHC are not included in this
diagram.
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Table 2
Estimates of λ for Single and Combined Cohorts
λ
Single Cohort
AS cases vs 1958 1.07
AITD cases vs 1958 1.12
BC cases vs 1958 1.13
MS cases vs 1958 1.12
Mixed Cohorts
AS cases vs All Others 1.03
AITD cases vs All Others 1.05
BC cases vs All Others 1.04
MS cases vs All Others 1.06
IMMUNE cases vs BC and 58C 1.04
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